2002-08 Ranger Polaris New Grey760A Sport RZR utility 4X2 4x4 6x6 UTV cover seat ATV, Side-by-Side & UTV Seats


  1. Home
  2. 2002-08 Ranger Polaris New Grey760A Sport RZR utility 4X2 4x4 6x6 UTV cover seat
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Polaris Ranger 2002-08 New seat cover UTV 6x6 4x4 4X2 utility RZR Sport Grey760A
Condition: New other (see details) Manufacturer Part Number:

Does Not Apply

Fits: UTV Brand:

Unbranded





published on tue nov 09 2021

2002-08 Ranger Polaris New Grey760A Sport RZR utility 4X2 4x4 6x6 UTV cover seat ATV, Side-by-Side & UTV Seats

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

2002-08 Ranger Polaris New Grey760A Sport RZR utility 4X2 4x4 6x6 UTV cover seat ATV, Side-by-Side & UTV Seats

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS